East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Sacubitril and Valsartan Tablets, 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. Aurobindo Pharma’s Sacubitril and Valsartan Tablets,  are an AB-rated generic equivalent to the reference listed drug (RLD), Entresto® Tablets, manufactured by Novartis Pharmaceuticals Corporation.

Sacubitril and Valsartan Tablets are indicated to:

• Reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.